论文部分内容阅读
目的探讨替罗非班在急性ST段抬高型心肌梗死急诊经冠状动脉介入治疗术(PCI)中的应用。方法选择2010年3月至2013年12月收治的120例急性ST段抬高型心肌梗死患者,根据药物应用的不同随机分为观察组(67例)和对照组(53例),对照组患者在急诊PCI术前常规应用阿司匹林和氯吡格雷,观察组在对照组治疗的基础上加用替罗非班,观察两组患者术后TIMI血流分级、临床疗效及不良反应情况。结果治疗后观察组患者总有效率为92.54%,对照组为84.91%,两组间临床疗效比较差异有统计学意义(P<0.05);PCI术后TIMI血流分级中2级以下患者两组无统计学意义(P>0.05),3级患者观察组明显多于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为13.42%,对照组为16.98%,两组比较差异无统计学意义(P>0.05)。结论ST段抬高型心肌梗死患者行急诊PCI术前应用盐酸替罗非班能提高临床疗效,改善心肌细胞组织灌注,且不会增加出血并发症的发生率及不良反应发生率低。
Objective To investigate the application of tirofiban in the treatment of acute ST-segment elevation myocardial infarction by coronary intervention (PCI). Methods A total of 120 patients with acute ST-elevation myocardial infarction who were treated from March 2010 to December 2013 were randomly divided into observation group (67 cases) and control group (53 cases) according to different drug application. Patients in the control group Aspirin and clopidogrel were routinely administered before emergency PCI. The observation group was given tirofiban on the basis of the control group, and the postoperative TIMI flow classification, clinical efficacy and adverse reactions were observed. Results After treatment, the total effective rate was 92.54% in the observation group and 84.91% in the control group. There was significant difference between the two groups in clinical curative effect (P <0.05) There was no significant difference between the observation group and the control group (P> 0.05). The incidence of adverse reactions was 13.42% in the observation group and 16.98% in the control group, and the difference was statistically significant (P <0.05) The difference was not statistically significant (P> 0.05). Conclusions The application of tirofiban hydrochloride before ST-segment elevation myocardial infarction in patients with ST-segment elevation myocardial infarction can improve the clinical curative effect, improve myocardial tissue perfusion without increasing the incidence of bleeding complication and the incidence of adverse reactions.